Expert oncologist Marina Chiara Garassino, MD, reviews the case of a 72-year-old woman with advanced stage NSCLC and considers optimal treatment pathways.
EP. 1: A Patient Case of PD-L1–High Metastatic NSCLC: First-Line Treatment Options
Expert oncologist Marina Chiara Garassino, MD, reflects on a patient case of PD-L1–high metastatic NSCLC and outlines first-line treatment options in this setting.
EP. 2: Factors in Selecting First-Line Therapy for PD-L1–High Metastatic NSCLC
Comprehensive insight to factors that inform the optimal selection of first-line therapy for patients with PD-L1–high metastatic non–small cell lung cancer.
EP. 3: EMPOWER-Lung1: First-Line Cemiplimab Use in PD-L1–High Advanced NSCLC
Highlighting data from the EMPOWER-Lung1 trial, Marina Chiara Garassino, MD, considers the role of first-line cemiplimab in managing PD-L1–high metastatic NSCLC.
EP. 4: Potential Role for Chemoimmunotherapy in the 2L Setting of PD-L1–High Advanced NSCLC
Centering focus on the second-line setting of PD-L1–high metastatic NSCLC, a key opinion leader defines a potential role for chemoimmunotherapy,
EP. 5: PD-L1–High Advanced NSCLC: Future Directions in Care
Closing out her discussion on PD-L1–high metastatic NSCLC, Marina Chiara Garassino, MD, looks toward future evolutions in the treatment paradigm.
2 Clarke Drive Cranbury, NJ 08512